Dendreon (DNDN) Gets Takeover Buzz and a New Bull
Tweet
Share
E-mail
Get Alerts DNDN Hot Sheet
Join SI Premium – FREE
The rumor mill has found Dendreon Corp. (Nasdaq: DNDN) again.
Shares of the embattled maker of cancer drug PROVENGE are jumping 7 percent Wednesday as traders snap-up the stock on renewed hopes for a buyout. Volume is on pace to be double the norm.
Dendreon newer CEO John Johnson has an M&A past, having successfully sold ImClone to Eli Lilly & attempted to sell Savient.
That being said, investors won't likely sell out for anything less than $20 per share. With shares in the toilet at $6-$7, this seems highly unlikely any time soon.
Also helping Dendreon today is a new Buy rating at Summer Street. The firm set an aggressive $18 price target, which suggests 166 percent upside from current levels.
Shares of the embattled maker of cancer drug PROVENGE are jumping 7 percent Wednesday as traders snap-up the stock on renewed hopes for a buyout. Volume is on pace to be double the norm.
Dendreon newer CEO John Johnson has an M&A past, having successfully sold ImClone to Eli Lilly & attempted to sell Savient.
That being said, investors won't likely sell out for anything less than $20 per share. With shares in the toilet at $6-$7, this seems highly unlikely any time soon.
Also helping Dendreon today is a new Buy rating at Summer Street. The firm set an aggressive $18 price target, which suggests 166 percent upside from current levels.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bernstein on whether Hershey (HSY) could eventually step up to buy Mondelez (MDLZ)
- Nelson Peltz Prepares Bid For Wendy’s - FT
- Alibabato sell Lingxi Games in more than $2B deal - Reuters
Create E-mail Alert Related Categories
Momentum Movers, RumorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
